X4 Pharmaceuticals Announced New Clinical Data From Its Ongoing Phase 2 Trial Of Of Mavorixafor For Chronic Neutropenia, Showing Mavorixafor Was Generally Well Tolerated And Durably Increased Participants' Absolute Neutrophil Counts
Portfolio Pulse from Benzinga Newsdesk
X4 Pharmaceuticals announced new clinical data from its ongoing Phase 2 trial of mavorixafor for chronic neutropenia, showing the drug was generally well tolerated and durably increased participants' absolute neutrophil counts. 100% of evaluable participants at Month 6 achieved target ANC increase.
June 27, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
X4 Pharmaceuticals' Phase 2 trial of mavorixafor for chronic neutropenia shows promising results, with 100% of participants achieving target ANC increase at Month 6. The drug was well tolerated and showed durable increases in ANC levels.
The positive clinical data from the Phase 2 trial of mavorixafor is likely to boost investor confidence in X4 Pharmaceuticals. The fact that 100% of participants achieved the target ANC increase and the drug was well tolerated suggests strong potential for future success, which could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100